BioLife Solutions Announces Closing of Stirling Ultracold Acquisition and Expanded Partnership with Leading Global BioPharma CDMO

May 3, 2021

BOTHELL, Washington – BioLife Solutions, Inc. (NASDAQ: BLFS)

(“BioLife” or the “Company”), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has closed the previously announced acquisition of Stirling Ultracold (“Stirling”), a privately held manufacturer of ultra-low temperature (“ULT”) mechanical freezers.  BioLife issued 6,646,870 shares of common stock in exchange for 100% of the outstanding shares of Stirling.

Read more of this press release on Stirling Ultracold’s website: https://www.stirlingultracold.com/biolife-solutions-announces-closing-of-stirling-ultracold-acquisition-and-expanded-partnership-with-leading-global-biopharma-cdmo/?utm_campaign=Project%20Chill&utm_content=164974627&utm_medium=social&utm_source=linkedin&hss_channel=lcp-2174056

Also, at Columbus Business First: https://www.bizjournals.com/columbus/news/2021/05/03/forge-vc-round-part-of-growing-gene-therapy-huv.html